TAK-981's potency and its synergy with cytarabine for AML cells. (A) Dose-response curves of TAK-981 and cytarabine for 4 AML cell lines. The concentration values right beside each curve represent IC50 values. (B) Synergy between TAK-981 and cytarabine for 4 AML cell lines. (C) Combination index plots computed from the data in panel B by CompuSyn software. (D) Synergy between TAK-981 and several drugs for MOLM-14 cell line. (E) Combination index plots computed from the data in panel D by CompuSyn software. For panels B and D, different concentration ranges were used for each drug, and the error bars indicate standard deviation. For panels C and E, values below the dotted line at 1.0 indicate synergy. For panels A, B, and D, cell viability was measured by CCK-8 assay. Aza, azacitidine; Fa, fractions affected; Qui, quizartinib; TAK, TAK-981; Ven, venetoclax.
